Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 1
1951 1
1952 1
1955 1
1956 1
1958 1
1961 1
1962 4
1963 4
1964 8
1965 2
1966 7
1967 9
1968 5
1969 3
1970 7
1971 4
1972 12
1973 13
1974 25
1975 17
1976 27
1977 27
1978 24
1979 30
1980 30
1981 24
1982 22
1983 21
1984 26
1985 33
1986 35
1987 29
1988 38
1989 39
1990 34
1991 40
1992 46
1993 46
1994 32
1995 34
1996 45
1997 39
1998 45
1999 42
2000 47
2001 41
2002 59
2003 77
2004 73
2005 69
2006 76
2007 82
2008 100
2009 93
2010 123
2011 79
2012 103
2013 104
2014 99
2015 114
2016 118
2017 130
2018 155
2019 135
2020 142
2021 167
2022 158
2023 123
2024 132
2025 137
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,345 results

Results by year

Filters applied: . Clear all
Page 1
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. Freeman MW, et al. Among authors: murphy b. N Engl J Med. 2023 Feb 2;388(5):395-405. doi: 10.1056/NEJMoa2213169. Epub 2022 Nov 7. N Engl J Med. 2023. PMID: 36342143 Clinical Trial.
Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.
Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, Lombardi S, Nie H, Murphy B, Yang T, Wang C, Liao L, Goldman AR, Kannan T, Kossenkov AV, Drapkin R, Montaner LJ, Claiborne DT, Zhang N, Wu S, Zhang R. Zhou W, et al. Among authors: murphy b. Cancer Cell. 2023 Apr 10;41(4):740-756.e10. doi: 10.1016/j.ccell.2023.03.002. Epub 2023 Mar 23. Cancer Cell. 2023. PMID: 36963401 Free PMC article.
Stability of Protein Pharmaceuticals: Recent Advances.
Manning MC, Holcomb RE, Payne RW, Stillahn JM, Connolly BD, Katayama DS, Liu H, Matsuura JE, Murphy BM, Henry CS, Crommelin DJA. Manning MC, et al. Among authors: murphy bm. Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27. Pharm Res. 2024. PMID: 38937372 Review.
Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.
Robijns J, Nair RG, Lodewijckx J, Arany P, Barasch A, Bjordal JM, Bossi P, Chilles A, Corby PM, Epstein JB, Elad S, Fekrazad R, Fregnani ER, Genot MT, Ibarra AMC, Hamblin MR, Heiskanen V, Hu K, Klastersky J, Lalla R, Latifian S, Maiya A, Mebis J, Migliorati CA, Milstein DMJ, Murphy B, Raber-Durlacher JE, Roseboom HJ, Sonis S, Treister N, Zadik Y, Bensadoun RJ. Robijns J, et al. Among authors: murphy b. Front Oncol. 2022 Aug 30;12:927685. doi: 10.3389/fonc.2022.927685. eCollection 2022. Front Oncol. 2022. PMID: 36110957 Free PMC article.
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.
Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, Bianchi E, Branca D, Bueters T, Buist N, Ha SN, Hafey M, He H, Higgins J, Johns DG, Kerekes AD, Koeplinger KA, Kuethe JT, Li N, Murphy B, Orth P, Salowe S, Shahripour A, Tracy R, Wang W, Wu C, Xiong Y, Zokian HJ, Wood HB, Walji A. Tucker TJ, et al. Among authors: murphy b. J Med Chem. 2021 Nov 25;64(22):16770-16800. doi: 10.1021/acs.jmedchem.1c01599. Epub 2021 Oct 27. J Med Chem. 2021. PMID: 34704436
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.
Cheng PTW, Kaltenbach RF 3rd, Zhang H, Shi J, Tao S, Li J, Kennedy LJ, Walker SJ, Shi Y, Wang Y, Dhanusu S, Reddigunta R, Kumaravel S, Jusuf S, Smith D, Krishnananthan S, Li J, Wang T, Heiry R, Sum CS, Kalinowski SS, Hung CP, Chu CH, Azzara AV, Ziegler M, Burns L, Zinker BA, Boehm S, Taylor J, Sapuppo J, Mosure K, Everlof G, Guarino V, Zhang L, Yang Y, Ruan Q, Xu C, Apedo A, Traeger SC, Cvijic ME, Lentz KA, Tirucherai G, Sivaraman L, Robl J, Ellsworth BA, Rosen G, Gordon DA, Soars MG, Gill M, Murphy BJ. Cheng PTW, et al. Among authors: murphy bj. J Med Chem. 2021 Nov 11;64(21):15549-15581. doi: 10.1021/acs.jmedchem.1c01256. Epub 2021 Oct 28. J Med Chem. 2021. PMID: 34709814
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Freeman MW, et al. Among authors: murphy b. Hypertens Res. 2023 Jan;46(1):108-118. doi: 10.1038/s41440-022-01070-4. Epub 2022 Oct 20. Hypertens Res. 2023. PMID: 36266539 Free PMC article. Clinical Trial.
3,345 results